Moderna Stock Sinks. It Disappoints With Covid-19 Vaccine Forecast.
Portfolio Pulse from
Moderna's stock has declined following a disappointing forecast for its Covid-19 vaccine revenue, which is expected to be between $1.5 billion and $2.5 billion in 2025.
January 13, 2025 | 12:30 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Moderna's stock has declined due to a disappointing revenue forecast for its Covid-19 vaccine, expected to be between $1.5 billion and $2.5 billion in 2025.
The revenue forecast for Moderna's Covid-19 vaccine is lower than expected, which has led to a decline in its stock price. Investors likely anticipated higher revenue figures, and the announcement has negatively impacted market sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100